1,796,341 Shares in Replimune Group, Inc. (NASDAQ:REPL) Acquired by Boxer Capital Management LLC

Boxer Capital Management LLC bought a new position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,796,341 shares of the company's stock, valued at approximately $21,754,000. Replimune Group accounts for 1.8% of Boxer Capital Management LLC's holdings, making the stock its 14th largest holding. Boxer Capital Management LLC owned approximately 2.63% of Replimune Group as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Sterling Capital Management LLC boosted its stake in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after purchasing an additional 1,655 shares during the period. Tower Research Capital LLC TRC boosted its position in Replimune Group by 696.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company's stock valued at $82,000 after buying an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its position in Replimune Group by 8,798.9% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after buying an additional 8,183 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Replimune Group during the fourth quarter valued at about $137,000. Finally, Freestone Grove Partners LP acquired a new position in shares of Replimune Group in the fourth quarter worth about $140,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. BMO Capital Markets upped their target price on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright boosted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $19.43.

Replimune Group Price Performance

Shares of REPL stock remained flat at $10.01 during trading hours on Monday. 655,063 shares of the company were exchanged, compared to its average volume of 871,562. The company has a market cap of $770.92 million, a price-to-earnings ratio of -3.26 and a beta of 0.68. The company's fifty day simple moving average is $9.81 and its 200-day simple moving average is $11.61. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, equities analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.